Generating Genotype-Specific Aminoglycoside Combinations with Ceftazidime/Avibactam for KPC-Producing Klebsiella pneumoniae-Reference-Cited by-同舟云学术

Generating Genotype-Specific Aminoglycoside Combinations with Ceftazidime/Avibactam for KPC-Producing Klebsiella pneumoniae

Published:2021-08-17 Issue:9 Volume:65 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Huang Yanqin¹^ORCID,Sokolowski Karol¹,Rana Amisha¹,Singh Nidhi¹,Wang Jiping²,Chen Ke²,Lang Yinzhi³,Zhou Jieqiang³,Kadiyala Neera¹,Krapp Fiorella⁴,Ozer Egon A.⁵,Hauser Alan R.⁶^ORCID,Li Jian²^ORCID,Bulitta Jürgen B.³^ORCID,Bulman Zackery P.¹^ORCID

Affiliation:

1. Department of Pharmacy Practice, University of Illinois at Chicago College of Pharmacy, Chicago, Illinois, USA

2. Biomedicine Discovery Institute, Department of Microbiology, Monash University, Clayton, Australia

3. Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Orlando, Florida, USA

4. Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano Heredia, Lima, Peru

5. Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA

6. Department of Microbiology-Immunology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA

Abstract

Antibiotic combinations, including ceftazidime/avibactam (CAZ/AVI), are frequently employed to combat KPC-producing Klebsiella pneumoniae (KPC-Kp), though such combinations have not been rationally optimized. Clinical KPC-Kp isolates with common genes encoding aminoglycoside-modifying enzymes (AMEs), aac(6′)-Ib′ or aac(6′)-Ib , were used in static time-kill assays ( n = 4 isolates) and the hollow-fiber infection model (HFIM; n = 2 isolates) to evaluate the activity of gentamicin, amikacin, and CAZ/AVI alone and in combinations.

Funder

Chicago Biomedical Consortium

Australian National Health and Medical Research Council

HHS | National Institutes of Health

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00692-21

Reference48 articles.

1. CDC. 2019. Antibiotic resistance threats in the United States 2019. U.S. Department of Health and Human Services Centers for Disease Control and Prevention Atlanta GA. www.cdc.gov/DrugResistance/Biggest-Threats.html.

2. WHO. 2017. Global priority list of antibiotic-resistant bacteria to guide research discovery and development of new antibiotics. World Health Organization Geneva Switzerland.

3. In vitro antibacterial activity of ceftazidime/avibactam in combination against planktonic and biofilm carbapenemase-producing Klebsiella pneumoniae isolated from blood

4. Reduced Ceftazidime-Avibactam Susceptibility in KPC-Producing Klebsiella pneumoniae From Patients Without Ceftazidime-Avibactam Use History – A Multicenter Study in China

5. Multicenter Clinical and Molecular Epidemiological Analysis of Bacteremia Due to Carbapenem-Resistant Enterobacteriaceae (CRE) in the CRE Epicenter of the United States

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ceftazidime/avibactam alone or in combination with an aminoglycoside for treatment of carbapenem-resistant Enterobacterales infections: a retrospective cohort study;International Journal of Antimicrobial Agents;2024-09

2. Interaction of Acinetobacter sp. RIT 592 induces the production of broad-spectrum antibiotics in Exiguobacterium sp. RIT 594;Frontiers in Pharmacology;2024-08-01

3. Synergistic antibacterial activity of ceftazidime–avibactam in combination with colistin, gentamicin, amikacin, and fosfomycin against carbapenem-resistant Klebsiella pneumoniae;Scientific Reports;2024-07-30

4. Critical role of growth medium for detecting drug interactions in Gram-negative bacteria that model in vivo responses;mBio;2024-03-13

5. In vitro, in vivo and clinical studies comparing the efficacy of ceftazidime-avibactam monotherapy with ceftazidime-avibactam-containing combination regimens against carbapenem-resistant Enterobacterales and multidrug-resistant Pseudomonas aeruginosa isolates or infections: a scoping review;Frontiers in Medicine;2023-09-04